Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc./ US09061G1013 /
BM8
31/05/2024 07:57:14
|
Chg.
-0.4600
|
Volume |
Bid17:48:56 |
Ask17:48:56 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
68.6200EUR
|
-0.67%
|
- Turnover: - |
68.5000Bid Size: 330 |
68.5400Ask Size: 330 |
13.1 bill.EUR |
- |
- |
Business description
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
Management board & Supervisory board
CEO |
Jean-Jacques Bienaimé |
Management board |
Brian Mueller, Amy Wireman, Dr. Brinda Balakrishnan, Dr. C. Greg Guyer, G. Eric Davis, Henry J. Fuchs, Jeff Ajer, Philip Lo Scalzo |
Supervisory board |
Jean-Jacques Bienaimé, David Pyott, Dr. Dennis J. Slamon, Dr. Elaine J. Heron, Dr. V. Bryan Lawlis, Elizabeth Anderson, Mark Alles, Maykin Ho, Richard A. Meier, Robert Hombach, Willard H. Dere |
Company data
Name: |
Biomarin Pharmaceutical Inc. |
Address: |
770 Lindaro Street,San Rafael, California 94901, USA |
Phone: |
+1-415-506-6700 |
Fax: |
+1-415-3827889 |
E-mail: |
-
|
Internet: |
www.bmrn.com/ |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
31/12 |
Free Float: |
58.89% |
IPO date: |
01/07/1999 |
Investor relations
Name: |
Traci McCarty |
IR phone: |
+1-415-455-7558 |
IR Fax: |
- |
IR e-mail: |
IR@BMRN.com
|
Main Shareholders
Freefloat |
|
58.89% |
PRIMECAP Management Company |
|
9.67% |
The Vanguard Group |
|
8.88% |
Dodge & Cox |
|
8.05% |
BlackRock, Inc. |
|
7.62% |
Capital Research Global Investors |
|
6.89% |